The latest research study “Doxorubicin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global doxorubicin market size reached US$ 1.12 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.62 Billion by 2027, exhibiting a CAGR of 6.10% during 2022-2027.
Covid-19 Impact:
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Download free sample brochure (Exclusive Offer on this report): https://www.imarcgroup.com/doxorubicin-market/requestsample
Industry Definition and Application:
Doxorubicin (DOX) refers to a generic medicine that is used in the process of chemotherapy to treat cancer. It is eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. Doxorubicin is utilized as an injection solution or in lyophilized powder form to intravenously administer via a peripherally central venous catheter (CVC) or inserted central line catheter (PICC). In addition to this, it also finds extensive applications in treating various types of cancer, including bladder cancer, breast cancer, Kaposi’s sarcoma, lymphoma, Wilms’ tumor, non-Hodgkin’s lymphoma, acute lymphocytic leukemia, etc.
Global Doxorubicin Market Trends and Drivers:
The widespread product adoption in combination with other chemotherapeutic agents to cure a variety of carcinomas is primarily driving the doxorubicin market. Additionally, the escalating demand for minimally invasive (MI) surgical procedures and the expanding geriatric population who cannot undergo surgeries are augmenting the utilization of DOX as part of cancer treatment therapies. This, in turn, is catalyzing the market growth. Moreover, the rising investments in clinical trials to develop enhanced DOX formulations are positively influencing the global market. Apart from this, the growing consumer awareness towards the availability of doxorubicin is acting as another significant growth-inducing factor. Furthermore, government bodies across the countries are launching numerous favorable policies to support technological advancements in clinical oncology, such as digital microfluidics for on-chip biochemical analysis and intravenous free therapy, which is anticipated to fuel the doxorubicin market over the forecasted period.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=5677&flag=C
|
Doxorubicin Market Report Scope |
|
|
Report Coverage |
Details |
|
Market size value in 2021 |
US$ 1.12 Billion |
|
Market forecast in 2027 |
US$ 1.62 Billion |
|
Growth Rate |
CAGR of 6.10% from 2022 to 2027 |
|
Base year for estimation |
2021 |
|
Historical data |
2016-2021 |
|
Forecast period |
2022-2027 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
|
Segments covered |
Application, Distribution Channel and Region |
|
Regional scope |
North America, Europe, Asia-Pacific, Latin America, Middle East and Africa |
|
Key companies profiled |
Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc. |
|
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period, |
|
Customization preview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Report Segmentation:
The report has been segmented the market into following categories:
Breakup by Application:
- Breast Cancer
- Ovarian Cancer
- Multiple Myeloma
- Kaposi Sarcoma
- Leukemia
- Bone Sarcoma
- Endometrial Cancer
- Others
Breakup by Distribution Channel:
- Hospital and Retail Pharmacies
- Online Stores
- Others
By Geography:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
List of Major Key Players:
The major players in the market are Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.
Explore Latest Market Research Reports by IMARC Group:
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800